EDITOR IN CHIEF: Zhanna D. KOBALAVA, Corresponding Member of the Russian Academy of Sciences, MD, Professor, Head of the Department of Internal Medicine with a course of cardiology and functional diagnostics named after V.S. Moiseev, Medical Institute, RUDN University, Moscow, Russia; ISSN: 2313-0245 (Print) ISSN: 2313-0261 (online) Founded in 1997. Publication frequency: quarterly PUBLISHER: Peoples’ Friendship University of Russia named after Patrice Lumumba (RUDN University) Open Access: . APC: no article processing charge Peer-Review: double blind. Publication language: Russian, English Indexation: White List RCSI, Russian Index of Science Citation, Scopus, Google Scholar, Ulrich's Periodicals Directory, Dimensions, DOAJ
Peoples’ Friendship University of Russia named after Patrice Lumumba (RUDN University)
The right of authorship belongs to the authors of articles. The authors transfer the rights to use the article (including the use and distribution of an article in the Open Access) to the publisher of the journal on a non-exclusive license (Publishing Agreement (Public Offer)). At the same time, authors remain full rightsholders. Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'RUDN Journal of Medicine' The Federal State Autonomous Educational Institution of Higher Education "Peoples’ Friendship University of Russia named after Patrice Lumumba” (RUDN University), represented by the Vice-Rector for Scientific Work Andrey Aleksandrovich Kostin, acting under a Power of Attorney No 0036-09/25-122 dated 21.05.2025, hereinafter referred to as the Publisher, on the one hand, hereby offers to the public at large, hereinafter referred to as the Author, on the other hand, hereinafter collectively referred to as the Parties, to enter into this agreement, hereinafter referred to as the Agreement, regarding publication of scholarly materials, hereinafter referred to as the Article, in the Journal named 'RUDN Journal of Medicine', hereinafter referred to as the Journal, under the following terms. 1. General Terms and Conditions 1.1. Pursuant to Clause 2 of the Article 437 of the Russian Federation Civil Code, this Agreement shall be recognized as the public offer, hereinafter referred to as the Offer. Subject to Article 438 of the Russian Federation Civil Code, this Offer shall be deemed to have been completely and irrevocably accepted after the Author had submitted his/her materials by uploading those onto the network electronic system of the article acquisition for review available at the respective section of the Journal's site at URL: http://journals.rudn.ru/index.php/medicine/author/submit/1 on the Information and Communication Network known as the Internet, hereinafter referred to as the Internet. 1.2. Pursuant to the Russian Federation effective law as applicable to compliance with the copyright to electronic information resources, no materials from any site, electronic journal or project may be reproduced, in whole or in part, in any form, either in a hard or soft copy, without a prior consent from the Journal's authors and editorial staff, which may be expressed by posting a respective consent (open license Creative Commons Attribution International 4.0 CC BY-NC) in the relevant section of the Journal's site on the Internet. Whenever any published materials are used within the context of other documents, a reference to the original source needs to be specified. 1.3. The Journal is registered by the Federal Oversight Service for Communications, Information Technologies and Mass Communications (RosKomNadzor). 2. Terms Used in This Agreement The Author is an individual (or individuals) whose creative labor has produced the Article. The Offer Acceptance means a complete and irrevocable acceptance of the Offer under the terms specified in Clause 3 hereof (the Author accepts the Offer by submitting an application to the Publisher, i.e. by uploading the Article along with support materials onto the network electronic system of the article acquisition for review available at the respective section of the Journal's site at URL: http://journals.rudn.ru/index.php/medicine/author/submit/1 on the Internet). The Journal means an academic periodical named 'BULLETIN of Peoples’ Friendship University of Russia. Series Medicine'. The Application means an electronic request of the Author addressed to the Publisher for publishing the Article in the Journal by uploading the Article and support materials onto the network electronic system of the article acquisition for review available at the relevant section of the Journal's site at URL: http://journals.rudn.ru/index.php/medicine/author/submit/1 on the Internet). The Publisher is the Federal State Autonomous Educational Institution of Higher Education "Peoples’ Friendship University of Russia named after Patrice Lumumba” (RUDN), being the Journal's founder and publisher. The Article's Metadata means any materials in Russian and English intended to be included into the Science Citation database as per the original version of the Article such as the Article title; authors' details (full last name, first name, patronymic, present employer of each author with indication of the postal code, contact details (e-mail) of each author; abstract; keywords; topical classifications: UDC or any other bibliographic and library classification, and subject indices; bibliography (list of references). The Offer means this document (offer to the Author) to publish an Article by uploading it onto the site at URL: http://journals.rudn.ru/index.php/medicine/author/submit/1 on the Internet. The Publication means the act of publishing the Article in the Journal. The Journal's Editorial Staff means a creative team engaged in preparing the Journal for publication. The Editorial Board is an advisory body of the Journal's Editorial Office. The Article means a result of fundamental and applied scholarly efforts in the form of a scholarly material, scientific review material, scientific message, bibliographical review on specific topics of the scholarly study, and background information on Russian and foreign scientists submitted by the Author for publication in the Journal. The Parties mean the Author and the Publisher. The Article Requirements mean requirements to the materials published in the Journal's section named "To Authors" of the Journal's site at URL: http://journals.rudn.ru/index.php/medicine/about/submissions#authorGuidelines on the Internet. The Service means publication of the Article in the Journal as per the Author's application. 3. Subject Matter of the Agreement (Offer) 3.1. Subject to this Agreement, the Author shall provide the Publisher at no expense for the copyright duration as stated by the Russian Federation legislation with a non-exclusive license for use of the Author-created Article for the purpose of its publication in the Journal. 3.2. The rights to use this Article as assigned hereunder shall include but not limited to: reproduction of the Article or any part thereof, as well as its metadata in Russian and English in any material form whatsoever, including soft and hard copy forms, as an individual work product in periodicals and/or databases (whether local or web-based) owned by the Publisher and/or any other persons at the discretion of the Publisher; dissemination of the Article or any part thereof, as well as its metadata in Russian and English on any media as part of the Journal and/or databases owned by the Publisher or any other persons, at the discretion of the Publisher, or as an individual work product, worldwide via open access or by subscription without payment of any fee to the Author; making public the Article or any part thereof as well as its metadata in Russian and English so that any person could access the Article from any location and at any time of his/her choice (including via the Internet); issuing permissions to use the Article or any part thereof as well as its metadata in Russian and English to any third parties while notifying the Author by publishing the respective information on the Journal's site without payment of any fee to the Author; processing, including translation of the Article (including translation into foreign languages), and use of the processed (translated) Article in any manner specified above; any other rights, not expressly assigned to the Publisher hereunder, including patent rights to any processes, techniques or methods, and other means, described by the Author in the Article, as well as trademark rights, shall be retained by the Author. 3.3. No territorial restrictions will be applied to the use of rights to the Article. 3.4. This Agreement shall become effective from the time the Article is submitted to the Journal, i.e. uploaded along with support materials onto the network electronic system of the article acquisition for review available at the relevant section of the Journal's site at URL: http://journals.rudn.ru/index.php/medicine/author/submit/1 on the Internet, hereinafter referred to as the Article Upload. 3.5. The rights shall be assigned by the Author to the Publisher at no expense, and the Article publication in the Journal shall not result in any financial contribution to the Author. 3.6. If the Publisher decides to refuse to publish the Article in the Journal, this Agreement shall cease to be in force. A decision to refuse publication shall be sent to the Author via the e-mail address specified in the Application. 3.7. The Publisher undertakes, throughout the currency of this Agreement, to provide to the Author the services associated with publication of the Article on the Journal's site at URL: http://journals.rudn.ru/index.php/medicine on the Internet. 4. General Terms of the Services Provision 4.1. The Publisher shall provide the services to the Author only if: the Author submits all materials compliant with the Offer requirements by way of the Article Upload; the Author Accepts the Offer. 4.2. The services shall be provided to the Author free of charge. 4.3. If any materials submitted by the Author are found in breach of rules and requirements of this Offer, the Publisher shall have a right to refuse to publish those. 4.4. The Publisher shall not be responsible for any third-party unauthorized use of the data provided by the Author during the currency of this Agreement. 5. Rights and Responsibilities of the Parties 5.1. The Author warrants that: he/she is the valid holder of exclusive rights to the Article; rights granted to the Publisher hereunder were not earlier assigned and will not be assigned to any third parties prior to publication of the Article by the Publisher in the Journal; the Article contains all the references to cited authors and/or sources (materials) that are required by the effective copyright law; the Author has obtained all required licenses to results, facts and other borrowed materials used in the Article where the Author is not a copyright holder; the Article does not contain any materials that may not be published in public sources in accordance with the effective Russian Federation statutory instruments, and the Article publication and dissemination will not involve any disclosure of classified (confidential) information, including state secrets; the Author has familiarized himself with the editorial policy and ethical principles published on the Journal website (http://journals.rudn.ru/medicine/about/editorialPolicies) and the consequences of violating these principles, has advised other Co-authors of the terms of this Agreement and has received consents from all the Co-authors to conclude this Agreement under the terms hereunder. 5.2. The Author undertakes to: submit a manuscript of the Article as per the Requirements to articles; avoid using the soft copy of the Article produced by the Publisher for commercial purposes and in other periodicals; while preparing the Article for publication, the Author undertakes to: make edits specified by readers and approved by the Journal's Editorial Office in the text of the Article and/or revise the Article following the Publisher's request, where necessary; proofread the Article within the timeframes specified in the Journal publication schedule; make only such edits in the proof that are minimally required to correct errors made in the Article original and/or introduce factual and momentary changes. 5.3. The Author is entitled to: pass to any third party a soft copy of the published Article provided by the Publisher pursuant to Clause 5.4 hereof for the Article to be incorporated, in whole or in part, into a scientific information database or repository in order to promote academic or scholarly investigations or for informational and educational purposes subject to the Author, Journal and Publisher being properly referenced. 5.4. The Publisher undertakes to: publish the Author's Article, in soft or hard copy form, in the Journal in accordance with the terms hereof; provide the Author with the proof of the Article and make reasonable edits as requested by the Author, where required, following the Journal's Editorial resolution; provide the Author with the soft copy of the published Article by sending it to the Author's e-mail address within 15 business days of the Journal issue's publication; respect the Author's rights established by the effective law, protect those and use best endeavors to prevent any copyright infringements by third parties. 5.5. The Publisher is entitled to: carry out technical and literary editing of the Article such that its basic content would remain unchanged; review the Article and suggest appropriate changes to the Author, and elect not to publish the Article if the Author fails to introduce such changes; require from the Author and/or other persons that the Journal, Publisher, Author and any other copyright holder, as well as the title of the Article, Journal issue identification and a year of publication as specified in the Journal be properly referenced whenever the Journal and/or the Article, including any individual part or fragment thereof, are used by any of the above-mentioned individuals thereafter; publish preliminary and/or advertising information on the forthcoming publication of the Article in mass media and any other information sources; establish rules (conditions) for acceptance and publication of materials in the Journal. The Journal's Editorial Board, headed by the Editor-in-Chief, shall enjoy an exclusive right to accept and/or reject any materials submitted to the Journal's Editorial Office for publication purposes. No manuscript (tangible medium) submitted by the Author to the Journal's Editorial Office will be subject to return. The Journal's Editorial Staff will not enter into any correspondence regarding the rejection of the Article by the Journal's Editorial Board; suspend provision of services to the Author hereunder temporarily for technical, technological and other reasons preventing the services from being provided for the duration of remedial activities; suspend services hereunder in accordance with civil procedures if: the Article does not correspond to the topics covered by the Journal or by any part thereof, or the submitted material is found insufficient for the individual publication, or the Article design is found at variance with the requirements imposed; the Author is in breach of any other obligations assumed under the Offer arrangement; introduce changes to the Offer as per the procedure established by the Offer. 5.6. Unless otherwise provided or stated herein, the Parties shall refer to the effective legislation of the Russian Federation. 6. Offer Acceptance and Conclusion of the Agreement. The Term of the Agreement 6.1. This Agreement shall become effective when concluded, i.e. when the Author Accepts the Offer by sending an application to the Publisher, that is, by uploading the Article (Article Upload), and remain in effect for five years. 6.2. The Offer Acceptance constitutes an Agreement made in writing (Articles 438 and 1286.1 of the Russian Federation Civil Code) under the Offer terms. 6.3. Unless any of the Parties sends to the other Party a written notification of the Agreement termination no later than two months prior to the end of the specified five-year period, the duration of the Publisher's copyright to the Work shall be automatically extended by the similar period. The number of extensions is not limited. 6.4. The term of the Agreement may not exceed the duration of exclusive rights to the Article pursuant to the Russian Federation legislation. 6.5. Whenever the Author assigns (disposes of) its exclusive rights to the Work to any third party, this Agreement shall remain in effect. 7. Agreement Modification and Termination Procedure 7.1. The Publisher shall have a right to unilaterally modify the terms of this Agreement by giving a prior notice to the Author, at least ten (10) calendar days before such modifications become effective, to the Author's e-mail address specified in the Author's application or via the Journal's site. These modifications shall become effective from the date specified in the respective notice. 7.2. If the Author disagrees with any modification in the terms of this Agreement, the Author shall have a right to submit a written notice of his/her withdrawal from this Agreement by uploading it onto the network electronic system of the article acquisition for review, available at the relevant section of the Journal's site at URL: http://journals.rudn.ru/index.php/medicine/author/submit/1 on the Internet. 7.3. This Agreement may be terminated early: at any time by mutual agreement of the Parties; or otherwise as stipulated herein. 7.4. The Author shall have a right to cancel this Agreement unilaterally by sending the Publisher a respective notice in writing at least sixty (60) calendar days prior to the intended date of the Author's Article publication in the Journal. 7.5. The termination of this Agreement for any reasons shall not release the Parties from responsibility for breach of any Agreement terms during the currency hereof. 8. Liability 8.1. A Party which has failed to perform its obligations under this Agreement, either in full or in part, shall be held liable pursuant to the Russian Federation legislation in force. 8.2. All the data provided by the Author shall be trustworthy. The Author shall be responsible for completeness and reliability of the data provided to the Publisher. The use of untrustworthy information obtained from the Author shall not entail any responsibility upon the Publisher for any adverse effects resulting from its actions based on such untrustworthy information. 8.3. The Author shall take full personal responsibility for compliance with the requirements of the Russian Federation law on advertising, protection of copyright and related rights, protection of trademarks and service marks, and protection of consumer rights. 8.4. The Publisher shall not be held responsible hereunder for: any actions resulting directly or indirectly from the actions of the Author; any loss incurred by the Author whether or not the Publisher was in a position to predict such loss. 8.5. The Publisher shall be relieved from any responsibility for non-compliance with the terms of this Agreement if such non-compliance is a result of a force-majeure event such as an act of state authorities, including adoption of legal instruments, fire, flood, earthquake, other natural calamities, loss of power and/or computer network failure, strikes, civil commotions, riots, and any other similar events. 9. Dispute Resolution Procedure 9.1. Any disputes and disagreements shall be resolved by the Parties by negotiations, and if the Parties fail to reach an agreement, these shall be resolved in accordance with the effective law of the Russian Federation. 9.2. If any disagreements remain unresolved, the Parties shall settle those at the location of the Publisher in accordance with the effective law of the Russian Federation. 10. Miscellaneous 10.1. Any notifications, messages, requests etc., excluding documents which need to be forwarded in original form pursuant to the Russian Federation legislation, shall be deemed to have been received by the Author, if delivered (sent) by the Publisher via the Journal's site, including by publishing those, by fax or e-mail specified in the Application, or using other communication facilities. The Parties acknowledge validity of notifications, messages, requests etc. delivered (sent) using the above-listed methods. 10.2. Where the Publisher becomes subject to any claims related to non-compliance with an exclusive copyright or other intellectual property right of any third party during the writing of the Article or in connection with conclusion of this Agreement by the Author, the Author undertakes to: immediately upon receipt of a Publisher's notification, take measures to settle disputes with such third party, and, where necessary, join the litigation in favor of the Publisher and use its best endeavors to exclude the Publisher from the defendants; reimburse the legal cost, expenses and loss incurred by the Publisher as a result of application of a pre-award relief and measures for execution of a judgment, and damages paid by the Publisher to any third party for the infringement of exclusive copyright and/or other intellectual property rights, as well as other expenditures incurred by the Publisher as a result of infringement by the Author of any warranties provided hereunder. 10.3. Subject to Article 6 of the Federal Law On Personal Data No. 152-FZ dated July 27, 2006, for the period from the conclusion of this Agreement and until the discharge of Parties obligations hereunder, the Author expresses his/her consent to processing of the following personal data by the Publisher: last name, first name, patronymic; taxpayers identification number (TIN); place and date of birth; citizenship details; ID document details; registration and actual location address; e-mail address; mailing address with postal code; contact phone numbers; fax numbers; and details of the employers. 10.4. The Publisher is entitled to process the above personal data for the purpose of this Agreement performance, including for provision of information and reference services to the Author. The processing of personal data shall be understood to mean any handing (operations) with personal data, including collection, systematization, accumulation, storage, refinement (update, alteration), use, distribution (including transfer to third parties), depersonalization, blocking and deletion of personal data in accordance with the effective Russian Federation legislation. 10.5. Where permitted by the Russian Federation legislation, the Author is entitled to withdraw his/her consent to processing of personal data as listed in Clause 10.3 by forwarding a respective notice to the Publisher. Upon receipt of such notice, the Publisher has a right to suspend services. 10.6. The Author will, on a goodwill basis, submit his/her details (and details of each Co-Author subject to their prior consent) to the Journal's Editorial Office consisting of his/her: last name, first name, patronymic, academic rank, academic degree, job title, employer details (name and mailing address), work phone number and e-mail address for the purpose of its general publication in the Journal along with the Article. 11. Registered Address and Particulars of the Publisher Federal State Autonomous Educational Institution of Higher Education "Peoples’ Friendship University of Russia named after Patrice Lumumba” (RUDN University) Address: 6 Mikluho-Maklaya str., Moscow, 117198, Russian Federation TIN 7728073720, CRR 772801001, PSRN 1027739189323. Vice Rector for Scientific Work A.A. Kostin
Deciphering the role of angiotensin converting enzyme2 in health and diseases
Relevance. Angiotensin converting enzyme 2 (ACE 2) is recognised as a significant regulator of cardiovascular and pulmonary homeostasis owing to its involvement in the renin-angiotensin system (RAAS). This extensive review addresses ACE 2’s conventional role in converting Angiotensin II (Ang II) to the Angiotensin-(1-7) to its broader implications in cardiovascular illness, pulmonary pathology, metabolic diseases, and cancers. Conclusion. Recent research has shed light on ACE2’s significance beyond its enzymatic capabilities, specifically as a cellular receptor of various pathogens. Furthermore, recent evidence shows that ACE2 is involved in inflammation, glucose metabolism, and gut microbiome modulation. The tissue distribution patterns, regulatory mechanisms, and therapeutic possibilities show its dual role as a protective factor in and a possible entryway for the viral infections. Understanding these multiple processes in health and disease state serves to be essential in establishing tailored treatments for the diseases. This review outlines the existing understanding of ACE 2 and emphasizes areas for further research, notably its potential as a therapeutic target. Furthermore, we have discussed the challenges and future directions in ACE2-based therapeutics.
Copyright (c) 2026 Sivasakthivel S., Ramani P. https://creativecommons.org/licenses/by-nc/4.0
Differences in the ratio of the peripheral blood phospholipid fractions among residents of different climatic and geographic territories
Relevance. A key element of human adaptation to the complex of extremе ecological factors is intensification of the energy metabolism. Mobilization of energy resources may lead to modification of the biological membranes and, as a consequence, to change their functional activity. Evaluation of the persistent imbalance degree on the level of phospholipid fractions may contribute to early diagnosis of the maladaptive states. Aim: an analysis of the levels of phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylethanolamine (PE) and sphingomyelin (SM) in the peripheral blood of the population in the Arctic and subarctic region of Russia, as well as the Southern Caucasus inhabitants. Materials and Methods. From 2010 to 2018, 687 people of both sexes aged 22 to 60 years were examined. The participants were divided into the following groups: 1) natives of the Russian Arctic region (AR); 2) residents of the subarctic region of Russia (SR); 3) residents of the South Caucasus (JUR). The level of the phospholipids was assessed using the thin-layer chromatography method. The results are presented in percentage terms. Results and Discussion. The residents of the AR revealed lower PS and higher PE levels compared to those of SR and JUR natives. At the same time, the AR individuals in the phospholipid spectrum reveal a relative decrease in the share of PC. Unlike the AR natives, the low PS content in the SR residents’ peripheral blood did not affect the overall pool of the phospholipids, which is within similar variation limits regarding the natives of the JUR. The SM medians in the compared groups had no statistically significant differences. Conclusion. The complex of adaptive alterations in the human body under Arctic conditions is associated with mobilization of mechanisms aimed at increasing physical fluidity of the biological membranes, which may indicate a significant increase in their permeability and intensification of receptor and enzymatic activity in cells.
Copyright (c) 2026 Shengof B.A., Bichkaeva F.A., Nesterova E.V. https://creativecommons.org/licenses/by-nc/4.0
Heart rhythm regulation during postural changes in female students depending on the parasympathetic centers excitability
The aim of this study was to investigate the features of heart rate variability during postural changes in women, depending on the excitability of parasympathetic centers and of the menstrual cycle phase. Material and Methods. 47 female students from Ivanovo State Medical University participated in the study. The average age of participants was 19.2±0.16 years. The study took place during the follicular and luteal phases of menstrual cycle, lasting an average of 29.3 ± 0.4 days. The features of parasymphathetic center excitability were assessed using the K30:15 ratio during the transition to an upright position. The electrocardiogram was recorded for 5 minutes using a computer electrocardiographic system Poly-spectrum (NeuroSoft, Ivanovo, Russia) both in the horizontal position and during active orthostasis, passive orthostasis and passive antiorthostasis. Results and Discussion. Based on the analysis of the dynamics of HRV indicators, it was found that the transition from a supine position to an upright body position was accompanied by a decrease in the influence of the vagus nerve on the heart. With active orthostasis, this does not depend on the excitability of the parasympathetic system and the phase of the menstrual cycle. While with passive orthostasis and reduced excitability of the parasympathetic centers, this is manifested in both phases of the cycle, and with normal excitability - only in the follicular phase. Antiorthostasis initiates an increase in parasympathetic activity in women with normal excitability only in the follicular phase, whereas in women with reduced excitability, there is a decrease in the influence of the vagus nerve in both phases of the cycle. Conclusion. The nature of circulatory system responses to changes in body position in women depend not only on type of posture but also on excitatory characteristics of parasympathetic nerves and menstrual cycle phases.
Copyright (c) 2026 Skorlupkin D.A., Golubeva E.K., Yarchenkova L.L. https://creativecommons.org/licenses/by-nc/4.0
Study of Ki-67 expression in transplanted fat graft in rats
Relevance. Autotransplantation of fat is used in plastic, reconstructive and aesthetic surgery. Currently, there are no studies aimed at studying the proliferative activity of autotransplants of fat after its various preoperative treatment. Aims. To evaluate Ki-67 expression in fat autografts as a marker of proliferation at distant time points in rats. Materials and Methods. Ki-67 protein expression was examined in adipocytes after fat autografting in rats after 30, 90 and 180 days. Three types of fat autografts were used: solid graft (group 3), scalpel-shredded graft (group 4) and homogenised fat in Luer Lock syringe (group 5). Group 1 consisted of intact animals and group 2 consisted of animals injected once in the withers with 0.9 % sodium chloride solution. Results and Discussion. The findings of the study indicated that, 30 days following the surgical procedure, the number of Ki-67-positive cells in the fat graft of group 3 was considerably higher than in the SCF of the recipient site of groups 3 and 5 (p < 0.001). The same marker was found to be significantly higher in the 4th group when compared to the control group of the autotransplantation of fat in the 3rd and 5th groups (p < 0.001), and to the 3rd group (p < 0.05). On the 90th day following surgery, the number of Ki-67-positive cells in the solid graft of group 3 was significantly higher than in the subcutaneous fat of the recipient site of the same group and group 5 (p < 0.001), as well as group 4 (p < 0.01). In group 4, the number of Ki-67-positive cells in subcutaneous fat at the injection site of fat autografts was significantly higher than in subcutaneous fat in group 3 (p < 0.001) and group 5 (p < 0.01). In the group of homogenised fat, this indicator was found to be statistically higher than in subcutaneous fat in the area of the autotransplantation site of the solid graft in group 3 (p < 0.05). Conclusion. The transplantation of a solid graft after a period of three months has been shown to stimulate the formation of subcutaneous fatty tissue at the site of its insertion. Furthermore, high activity of Ki-67 protein expression by cells in the fat graft itself has been observed. Moreover, at the time of autotransplantation of small-sized fat grafts (1×2×1 mm) and homogenised fat after 30 and 90 days, sprouting of connective-tissue strands containing Ki-67-positive cells and blood vessels was observed.
Copyright (c) 2026 Ibadullaeva S.S., Kastyro I.V., Dyachenko Y.E., Lavrentyeva E.A., Khlystalov M.V., Moroz S.E., Ganshin I.B., Popadyuk V.I., Kartasheva A.F., Korolev A.G., Barannik M.I., Sarygin P.V. https://creativecommons.org/licenses/by-nc/4.0
Highly differentiated cells in the therapy of acute respiratory distress syndrome
Relevance. Acute respiratory distress syndrome (ARDS) is a severe, life-threatening form of acute lung injury with a high mortality rate. In severe cases, pathological changes extend to the systemic level and manifest as cytokine storm syndrome. The lack of effective treatment options underscores the importance of exploring therapeutic approaches, including cell therapy. Interest in this treatment option increased during the SARS-CoV-2 pandemic, as evidenced by the numerous clinical trials registered for the use of cell preparations to treat ARDS. The aim of the study: Thus, this review summarizes preclinical and clinical studies on using highly differentiated cells, including immune system cells, to treat ARDS. To this end, we will describe key points in the pathogenesis of ARDS, including etiologic subtypes and stages, as well as the key cells involved and the results of their use in ARDS therapy. This review highlights the potential of using alveolar cells type 1 and type 2, as well as epithelial cells, for rapid lung regeneration after ARDS. Currently, there are no data describing the use of neutrophils, which trigger primary pathological changes in the lungs, for ARDS treatment. The use of macrophages, which play a key role in ARDS pathogenesis, is limited by their ability to quickly repolarize. Natural killer cells (NK cells), regulatory T cells (Tregs), and invariant natural killer T (iNKT cells) have shown high efficacy in treating ARDS in preclinical and clinical studies. Conclusion. Thus, using NK cells, Tregs, and iNKT cells for ARDS cell therapy seems promising. However, the lack of standardized protocols for preparing and administering cell therapies, as well as small sample sizes, indicate the need for additional studies.
Copyright (c) 2026 Kiseleva V.V., Miroshnichenko E.A., Vishnyakova P.A., Kosyreva A.M., Elchaninov A.V., Fatkhudinov T.K. https://creativecommons.org/licenses/by-nc/4.0
Association of BAP1 polymorphisms with development of uveal melanoma
Relevance. Uveal melanoma is a rare form of cancer that originates in the eye, most frequently arises in the choroid (90%). BAP1 is a tumor suppressor gene, mutations in this gene were found in 40-84% of primary UM. Given many investigators have proven the association of mutations in the BAP1 gene with UM. Aim: our study aims to figure out UM associated polymorphisms by sequencing DNA in exon 10, exon 11, exon 15, exon 16, and exon 17 as well as to assess the role of BRCA1 mutations in risk of UM development. Materials and Methods. A total of 95 individuals recruited in the study, out of them 42 as a patient group, 23 as a risk group, and 30 as a control group. The target regions of BAP1 gene amplified by PCR were sequenced by Sanger method and BRCA1 was genotyped by real-time PCR using commercially produced kits. Results and Discussion. This study did not demonstrate presence of any polymorphisms in the sequenced regions of the BAP1 gene or the genotyped specific BRCA1 sites that are correlated with an increased risk of uveal melanoma development. Our findings do not deny the published strong association between BAP1 inactivating mutations and the UM disease. This study’s findings instead propose that within this targeted population, the molecular mechanisms for BAP1 loss-function may include aberrations other than changes in the examined exons. Conclusion. Consequently, we recommend future research that includes sequencing the entire BAP1 gene in larger sized samples and studying of other candidate genes.
Copyright (c) 2026 Mukhana L., Ahmed A.A., Gigani O.O., Saakyan S.V., Tsygankov Alexander Y.Y., Azova M.M. https://creativecommons.org/licenses/by-nc/4.0
Cardiovascular pathology in the structure of comorbidity and mortality of patients with rheumatoid arthritis
Relevance. Obtaining reliable data on the levels of cardiovascular morbidity and mortality among patients with rheumatoid arthritis remains important. These aspects of patient management are very important; they determine further therapeutic tactics and are aimed at reducing the risks of complications. Target - to analyze cardiovascular pathology in the structure of comorbidity and mortality of patients with RA in the cohort of patients of the Center for Responsible Rheumatology ″Induction″ LLC in the period 2015-2022. Materials and Methods. A sample of 1020 patients with a reliable diagnosis of RA, established according to the classification criteria (ACR/EULAR, 2010), who were treated at the LLC Center for Responsible Rheumatology ″Induction″, was made. The average age was 55.3 ± 1.8 years, women predominated (88.8%). Comorbid status was assessed on the basis of lifetime consultations and analysis of medical documentation of the examined patients according to a developed chart, including a specified cardiovascular disease, as well as the fact of death. A systematic review of scientific works (2019-2024) on rheumatoid arthritis in the aspect of cardiovascular pathology was carried out. Results and Discussion. The incidence of cardiovascular pathologies in patients with RA, according to numerous studies (2019-2024), varies widely. Hypertension, coronary artery disease, heart failure, cardiac rhythm and conduction disorders, and atherosclerotic cardiovascular diseases occupy the leading place in prevalence. Patients with RA in the study cohort were characterized by a complex comorbidity structure. Cardiovascular pathology is the most common (42.29%). Respiratory diseases (23.07%), COVID-19 (11.53%), and Blastomatosis (7.69%) follow it. Acute pancreatitis complicated by pancreatic necrosis, bronchial asthma, lymphocytic leukemia, hypothyroidism, autoimmune thyroiditis, diabetes mellitus were recorded in no more than 3.85% of the cohort. Cardiovascular disorders included ischemic heart disease (30.76%) and hypertension (11.53%). The three main causes of death in patients with RA included cardiovascular, respiratory diseases, and sepsis. The leading position was occupied by cardiovascular events (47.83%), predominantly acute myocardial infarction (30.43%). Conclusion. An analysis of new data on the place of cardiovascular diseases in the structure of comorbidity and mortality of patients in the Stavropol Territory of the LLC “Center for Responsible Rheumatology ″Induction″ cohort with an established diagnosis of RA was carried out. The information obtained is useful for a better understanding of the clinical portrait of RA patients with cardiovascular pathology, and can be taken into account by rheumatologists to optimize management tactics for RA and the risk of cardiovascular events.
Copyright (c) 2026 Shchendrigin I.N., Lila A.M., Piskov S.I., Dimitriadi A.I. https://creativecommons.org/licenses/by-nc/4.0
Relationships between linear-quadratic parameters for cells irradiated in the presence and absence of cisplatin
Relevance. According to experimental data, administration of the drug cisplatin into the tumor during radiation therapy can increase its effectiveness. To date, there is no model that can predict the effectiveness of such therapy. The development of such a model is an important task for planning therapy. The goal of this work is to find analytical relationships for the survival of cells exposed to the combined effect of radiation and cisplatin in vitro. Materials and methods. Based on digitized experimental data on cell survival from a number of publicly published works, the corresponding linear-quadratic (LQ) approximation coefficients for survival were found for irradiation without the drug \( \alpha_R , \beta_R \), and for combined exposure to radiation and cisplatin \( \alpha_{RC} , \beta_{RC} \). Next, a regression analysis of the resulting set of coefficients and cell survival when exposed to cisplatin alone \( S_C \) was performed. Results and Discussion.\( \alpha_{RC} \) was found to be statistically dependent on \( \alpha_R, \beta_R \) and \( S_C \). This dependence could be described by several models, the best of which in terms of a number of indicators was \( \alpha_{RC} = \alpha_R + \alpha_R \ln S_C \), where \( \alpha = -4.27 \pm 0.57 \) is a parameter that is the same for all cell types and experimental conditions. It was found that \( \beta_{RC} \) is statistically dependent on \( \beta_R \). No signs of dependence of \( \beta_{RC} \) on \( \alpha_R \) and \( S_C \) were found. The best model for \( \beta_{RC} \) was \( \beta_{RC} = \beta_R \). These models are simple, but they allow predicting the value of cell survival under the combined effect of radiation and cisplatin \( S_{RC} \) from the values \( \alpha_R , \beta_R \) and \( S_C \) only approximately. The obtained models are collated with kinetic equations and a mechanistic interpretation is given, which is based on the hypothesis of a decrease in the rate of recovery of cells from potentially lethal lesions r , with an increase in the radiation dose and cisplatin concentration. Conclusion. The type of statistical dependence of LQ coefficients \( \alpha_{RC} \) and \( \beta_{RC} \) on \( \alpha_R , \beta_R \) and \( S_C \) has been found. In the case of high toxicity of cisplatin (low values of \( S_C \)), the combination of the above-mentioned models for \( \alpha_{RC} \) and \( \beta_{RC} \) allows to make a useful for practical application prediction of cell survival \( S_{RC} \). The results of this work will help for the future construction of more complex models of the combined effects of radiation and cisplatin, and may also have practical application in the case mentioned above.
Copyright (c) 2026 Konobeev I.A., Kurachenko Y.A., Sheino I.N. https://creativecommons.org/licenses/by-nc/4.0
Motivation comparative characteristics of students studying in medical specialties in medical universities
Relevance. The Far Eastern Federal District is a territory of advanced development, requiring a large number of specialists. Healthcare work is one of the most complex and demanding jobs, with high psychological stress, requiring attentiveness, endurance, and a high work ethic. Medical education has its own specifics; even in their first years, at least 80 % of students face a range of challenges: stress, sleep deprivation, fatigue, and other factors, which have negative consequences for learning, behavior, and communication, and impact their health. Building a motivational system is one of the most important steps in studying at medical universities. A highly motivated student will be engaged in the learning process, and therefore will study voluntarily and actively master the curriculum. Therefore, studying the motivation of medical students at medical schools is relevant. The aim of this study was to conduct a comparative analysis of the interaction between motivation to learn and the health status of medical students at medical universities in the Far East. Materials and Methods. Within the framework of the educational, scientific and industrial cluster «Far Eastern» on the basis of cooperation agreements, within the framework of social partnership of educational organizations of higher education and interaction of universities of the Far Eastern region, the following universities participated in the study: Far Eastern State Medical University (FESM), Amur State Medical Academy (ASMA), North-Eastern Federal University named after M.K. Ammosov (NEFU), Far Eastern Federal University (FEFU), Pacific State Medical University (TSMU). The health status of 2,676 first- to fifth-year students aged 17-24 was studied. The study utilized health group data obtained as a result of medical examinations and preventive checkups, the academic motivation scales (AMS) questionnaire, and self-assessment using a developed individual questionnaire. Students from Tver State Medical University, Far Eastern Federal University, and Far Eastern State Medical University completed the survey in the university classroom using printed questionnaires, while students from North-Eastern Federal University and Altai State Medical Academy participated in the survey using Google forms online. The Statistica 12.0 software package and the analytical functions of Microsoft Office Excel were used for mathematical and statistical processing. Results and Discussion. The conducted comparative characteristics of motivation for learning of students in medical specialties in medical universities of the Far East revealed a high intrinsic motivation for learning from 3.4 to 4.9. The highest values in assessing the motivation to achieve were among students of NEFU - 4.07, in TSMU and ASMA this criterion was 4.0. A relationship between the level of external and internal motivation with the health status of students was revealed. Students with health group 3 showed significant (group 3B p = 0.55) cognitive motivation, strong, almost absolute (p = 0.9) - external motivation and high motivation for achievement. Introjected motivation was weak (from p = 0.2 to p = 0.344) and did not depend on the health group. Conclusion. The relationship between extrinsic and intrinsic motivation for learning and health status among medical students at medical universities was identified and studied.
Copyright (c) 2026 Krukovich E.V., Kuznetsov V.V., Krukovich A.A., Petukhov R.A. https://creativecommons.org/licenses/by-nc/4.0